Exhibit 99

This press release contains information about Chemed’s EBITDA, Adjusted EBITDA, and Adjusted Diluted EPS, which are not measures derived in accordance with GAAP and which exclude components that are important to understanding Chemed’s financial performance. In reporting its operating results, Chemed provides EBITDA, Adjusted EBITDA and Adjusted Diluted EPS measures to help investors and others evaluate the Company’s operating results, compare its operating performance with that of similar companies that have different capital structures and evaluate its ability to meet its future debt service, capital expenditures and working capital requirements. Chemed’s management similarly uses EBITDA, Adjusted EBITDA, and Adjusted Diluted EPS to assist it in evaluating the performance of the Company across fiscal periods and in assessing how its performance compares to its peer companies. These measures also help Chemed’s management to estimate the resources required to meet Chemed’s future financial obligations and expenditures. Chemed’s EBITDA, Adjusted EBITDA and Adjusted Diluted EPS should not be considered in isolation or as a substitute for comparable measures calculated and presented in accordance with GAAP. We calculated Adjusted EBITDA Margin by dividing Adjusted EBITDA by service revenue and sales. A reconciliation of Chemed’s net income to its EBITDA, Adjusted EBITDA and Adjusted Diluted EPS is presented in the tables following the text of this press release.

SAFE HARBOR STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 REGARDING FORWARD-LOOKING INFORMATION

Statements in this press release contain forward-looking statements within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as “anticipate,” “intend,” “plan,” “goal,” “seek,” “believe,” “project,” “estimate,” “expect,” “strategy,” “future,” “likely,” “may,” “should,” “will” and similar references to future periods and are based upon assumptions subject to certain known and unknown risks, uncertainties, contingencies and other factors, including, but not limited to, the impact of laws and regulations on Chemed’s operations, including Medicare Cap and Medicare reimbursement rates, Chemed’s estimates of the effect of Medicare Cap on VITAS’ revenues and future prospects, Chemed’s expectations regarding VITAS’ patient mix and Chemed’s expectations regarding demand for Roto-Rooter’s services.

Because forward looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of Chemed’s control. Chemed’s actual results and financial condition may differ materially from those

indicated in the forward-looking statements included in this press release, including as a result of the risks described above and those described in the Chemed’s Annual Report on Form 10-K for the year ended December 31, 2025 and in its Quarterly Reports filed in 2026. Any forward-looking statement made by Chemed in this press release is based only on information currently available to Chemed and speaks only as of the date on which it is made. Chemed undertakes no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.


CHEMED CORPORATION AND SUBSIDIARY COMPANIES
CONSOLIDATED STATEMENTS OF INCOME
(in thousands, except per share data)(unaudited)

	Three Months Ended June 30,				Six Months Ended June 30,
	2026		2025		2026		2025
Service revenues and sales	$	673,251	$	618,798	$	1,330,764		1,265,741
Cost of services provided and goods sold		451,780		434,105		893,529		864,635
Selling, general and administrative expenses (aa)		115,203		100,323		229,524		205,910
Depreciation		14,267		13,689		28,570		27,134
Amortization		2,719		2,571		5,289		5,143
Other operating expense		78		26		70		77
Total costs and expenses		584,047		550,714		1,156,982		1,102,899
Income from operations		89,204		68,084		173,782		162,842
Interest expense		(1,789)		(443)		(2,301)		(772)
Other income--net (bb)		3,914		3,474		8,688		4,719
Income before income taxes		91,329		71,115		180,169		166,789
Income taxes		(23,626)		(18,622)		(46,164)		(42,539)
Net income	$	67,703	$	52,493	$	134,005	$	124,250
Earnings Per Share
Net income	$	5.14	$	3.60	$	9.98	$	8.51
Average number of shares outstanding		13,174		14,591		13,423		14,606
Diluted Earnings Per Share
Net income	$	5.13	$	3.57	$	9.97	$	8.43
Average number of shares outstanding		13,199		14,703		13,442		14,733

(aa) Selling, general and administrative ("SG&A") expenses comprise (in thousands):

	Three Months Ended June 30,				Six Months Ended June 30,
	2026		2025		2026		2025
SG&A expenses before long-term incentive compensation
and the impact of market value adjustments related to
deferred compensation plans	$	109,256	$	98,552	$	218,187	$	202,312
Market value adjustments related to deferred
compensation trusts		3,699		918		7,584		88
Long-term incentive compensation		2,248		853		3,753		3,510
Total SG&A expenses	$	115,203	$	100,323	$	229,524	$	205,910

(bb) Other income--net comprises (in thousands):
	Three Months Ended June 30,				Six Months Ended June 30,
	2026		2025		2026		2025

Market value adjustments related to deferred
compensation trusts	$	3,699	$	918	$	7,584	$	88
Interest income		214		2,555		1,104		4,631
Other		1		1		-		-
Total other income--net	$	3,914	$	3,474	$	8,688	$	4,719


CHEMED CORPORATION AND SUBSIDIARY COMPANIES
CONSOLIDATED BALANCE SHEETS
(in thousands, except per share data)(unaudited)

	June 30,
	2026		2025
Assets
Current assets
Cash and cash equivalents	$	40,222	$	249,904
Accounts receivable less allowances		188,634		184,880
Inventories		7,630		9,148
Prepaid income taxes		17,646		14,239
Prepaid expenses		37,103		33,206
Total current assets		291,235		491,377
Investments of deferred compensation plans held in trust		148,153		129,560
Properties and equipment, at cost less accumulated depreciation		208,499		202,281
Lease right of use asset		142,535		131,948
Identifiable intangible assets less accumulated amortization		78,601		87,360
Goodwill		699,398		666,996
Other assets		11,164		8,325
Total Assets	$	1,579,585	$	1,717,847
Liabilities
Current liabilities
Accounts payable	$	84,713	$	50,864
Accrued insurance		72,455		66,888
Accrued compensation		63,794		54,688
Short-term lease liability		41,277		43,700
Other current liabilities		57,607		47,746
Total current liabilities		319,846		263,886
Deferred income taxes		15,050		12,703
Deferred compensation liabilities		146,986		127,699
Long-term debt		140,000		-
Long-term lease liability		113,516		101,861
Other liabilities		13,677		13,213
Total Liabilities		749,075		519,362
Stockholders' Equity
Capital stock		37,613		37,593
Paid-in capital		1,617,125		1,576,165
Retained earnings		3,073,331		2,831,540
Treasury stock, at cost		(3,900,000)		(3,249,115)
Deferred compensation payable in Company stock		2,441		2,302
Total Stockholders' Equity		830,510		1,198,485
Total Liabilities and Stockholders' Equity	$	1,579,585	$	1,717,847


CHEMED CORPORATION AND SUBSIDIARY COMPANIES
CONSOLIDATED STATEMENTS OF CASH FLOWS
(in thousands)(unaudited)

	For the Six Months Ended June 30,
	2026		2025
Cash Flows from Operating Activities
Net income	$	134,005	$	124,250
Adjustments to reconcile net income to net cash provided
by operating activities:
Depreciation and amortization		33,859		32,277
Stock option expense		18,302		18,307
Benefit for deferred income taxes		(4,262)		(13,243)
Noncash long-term incentive compensation		3,633		3,273
Noncash directors' compensation		1,191		1,123
Legal settlements		548		-
Amortization of debt issuance costs		163		160
Changes in operating assets and liabilities, excluding
amounts acquired in business combinations:
Increase in accounts receivable		(6,716)		(13,466)
Increase in inventories		(87)		(955)
Increase in prepaid expenses		(10,285)		(7,232)
Increase/(decrease) in accounts payable and
other current liabilities		9,174		(12,449)
Change in current income taxes		(8,985)		(10,764)
Net change in lease assets and liabilities		292		(72)
(Increase)/decrease in other assets		(9,489)		48,426
Increase in other liabilities		11,191		1,521
Other sources		498		194
Net cash provided by operating activities		173,032		171,350
Cash Flows from Investing Activities
Business combinations, net of cash acquired		(33,540)		(225)
Capital expenditures		(32,639)		(29,088)
Proceeds from sale of fixed assets		422		480
Other uses		(270)		(322)
Net cash used by investing activities		(66,027)		(29,155)
Cash Flows from Financing Activities
Proceeds from revolving line of credit		491,480		-
Payments on revolving line of credit		(351,480)		-
Purchases of treasury stock		(287,521)		(76,168)
Change in cash overdrafts payable		23,305		309
Dividends paid		(16,049)		(14,542)
Proceeds from exercise of stock options		2,731		27,152
Capital stock surrendered to pay taxes on stock-based compensation		(1,482)		(8,484)
Debt issuance costs		(1,349)		-
Other (uses)/sources		(933)		1,092
Net cash used by financing activities		(141,298)		(70,641)
(Decrease)/increase in Cash and Cash Equivalents		(34,293)		71,554
Cash and cash equivalents at beginning of year		74,515		178,350
Cash and cash equivalents at end of period	$	40,222	$	249,904


CHEMED CORPORATION AND SUBSIDIARY COMPANIES
CONSOLIDATING STATEMENTS OF INCOME
FOR THE THREE MONTHS ENDED JUNE 30, 2026 AND 2025
(in thousands)(unaudited)
							Chemed
	VITAS		Roto-Rooter		Corporate		Consolidated
2026 (a)
Service revenues and sales	$	443,341	$	229,910	$	-	$	673,251
Cost of services provided and goods sold		337,691		114,089		-		451,780
Selling, general and administrative expenses		26,105		67,373		21,725		115,203
Depreciation		5,781		8,474		12		14,267
Amortization		27		2,692		-		2,719
Other operating expense		28		50		-		78
Total costs and expenses		369,632		192,678		21,737		584,047
Income/(loss) from operations		73,709		37,232		(21,737)		89,204
Interest expense		(54)		(185)		(1,550)		(1,789)
Intercompany interest income/(expense)		6,480		4,575		(11,055)		-
Other income—net		66		10		3,838		3,914
Income/(loss) before income taxes		80,201		41,632		(30,504)		91,329
Income taxes		(19,290)		(9,719)		5,383		(23,626)
Net income/(loss)	$	60,911	$	31,913	$	(25,121)	$	67,703

2025 (b)
Service revenues and sales	$	396,201	$	222,597	$	-	$	618,798
Cost of services provided and goods sold		320,644		113,461		-		434,105
Selling, general and administrative expenses		25,085		60,536		14,702		100,323
Depreciation		5,314		8,363		12		13,689
Amortization		26		2,545		-		2,571
Other operating expense/(income)		55		(29)		-		26
Total costs and expenses		351,124		184,876		14,714		550,714
Income/(loss) from operations		45,077		37,721		(14,714)		68,084
Interest expense		(47)		(129)		(267)		(443)
Intercompany interest income/(expense)		5,454		3,970		(9,424)		-
Other income—net		61		23		3,390		3,474
Income/(loss) before income taxes		50,545		41,585		(21,015)		71,115
Income taxes		(12,326)		(9,671)		3,375		(18,622)
Net income/(loss)	$	38,219	$	31,914	$	(17,640)	$	52,493


The "Footnotes to Financial Statements" are integral parts of this financial information.


CHEMED CORPORATION AND SUBSIDIARY COMPANIES
CONSOLIDATING STATEMENTS OF INCOME
FOR THE SIX MONTHS ENDED JUNE 30, 2026 AND 2025
(in thousands)(unaudited)

							Chemed
	VITAS		Roto-Rooter		Corporate		Consolidated
2026 (a)
Service revenues and sales	$	863,358	$	467,406	$	-	$	1,330,764
Cost of services provided and goods sold		663,157		230,372		-		893,529
Selling, general and administrative expenses		52,213		135,302		42,009		229,524
Depreciation		11,693		16,853		24		28,570
Amortization		53		5,236		-		5,289
Other operating expense/(income)		80		(9)		(1)		70
Total costs and expenses		727,196		387,754		42,032		1,156,982
Income/(loss) from operations		136,162		79,652		(42,032)		173,782
Interest expense		(104)		(321)		(1,876)		(2,301)
Intercompany interest income/(expense)		12,717		9,088		(21,805)		-
Other income—net		161		25		8,502		8,688
Income/(loss) before income taxes		148,936		88,444		(57,211)		180,169
Income taxes		(35,818)		(20,747)		10,401		(46,164)
Net income/(loss)	$	113,118	$	67,697	$	(46,810)	$	134,005

2025 (b)
Service revenues and sales	$	803,600	$	462,141	$	-	$	1,265,741
Cost of services provided and goods sold		633,451		231,184		-		864,635
Selling, general and administrative expenses		51,624		123,184		31,102		205,910
Depreciation		10,509		16,601		24		27,134
Amortization		52		5,091		-		5,143
Other operating expense/(income)		119		(42)		-		77
Total costs and expenses		695,755		376,018		31,126		1,102,899
Income/(loss) from operations		107,845		86,123		(31,126)		162,842
Interest expense		(95)		(261)		(416)		(772)
Intercompany interest income/(expense)		10,750		7,900		(18,650)		-
Other income—net		110		32		4,577		4,719
Income/(loss) before income taxes		118,610		93,794		(45,615)		166,789
Income taxes		(30,361)		(21,936)		9,758		(42,539)
Net income/(loss)	$	88,249	$	71,858	$	(35,857)	$	124,250


The "Footnotes to Financial Statements" are integral parts of this financial information.


CHEMED CORPORATION AND SUBSIDIARY COMPANIES
CONSOLIDATING SUMMARIES OF EBITDA
FOR THREE MONTHS ENDED JUNE 30, 2026 AND 2025
(in thousands)(unaudited)
							Chemed
	VITAS		Roto-Rooter		Corporate		Consolidated
2026
Net income/(loss)	$	60,911	$	31,913	$	(25,121)	$	67,703
Add/(deduct):
Interest expense		54		185		1,550		1,789
Income taxes		19,290		9,719		(5,383)		23,626
Depreciation		5,781		8,474		12		14,267
Amortization		27		2,692		-		2,719
EBITDA		86,063		52,983		(28,942)		110,104
Add/(deduct):
Intercompany interest expense/(income)		(6,480)		(4,575)		11,055		-
Interest income		(66)		(10)		(138)		(214)
Stock option expense		-		-		9,052		9,052
Long-term incentive compensation		-		-		2,248		2,248
Legal settlements		548		-		-		548
Acquisition expense		8		60		-		68
Adjusted EBITDA	$	80,073	$	48,458	$	(6,725)	$	121,806

2025
Net income/(loss)	$	38,219	$	31,914	$	(17,640)	$	52,493
Add/(deduct):
Interest expense		47		129		267		443
Income taxes		12,326		9,671		(3,375)		18,622
Depreciation		5,314		8,363		12		13,689
Amortization		26		2,545		-		2,571
EBITDA		55,932		52,622		(20,736)		87,818
Add/(deduct):
Intercompany interest expense/(income)		(5,454)		(3,970)		9,424		-
Interest income		(61)		(23)		(2,472)		(2,556)
Stock option expense		-		-		9,216		9,216
Long-term incentive compensation		-		-		853		853
Adjusted EBITDA	$	50,417	$	48,629	$	(3,715)	$	95,331

The "Footnotes to Financial Statements" are integral parts of this financial information.


CHEMED CORPORATION AND SUBSIDIARY COMPANIES
CONSOLIDATING SUMMARIES OF EBITDA
FOR THE SIX MONTHS ENDED JUNE 30, 2026 AND 2025
(in thousands)(unaudited)
							Chemed
	VITAS		Roto-Rooter		Corporate		Consolidated
2026
Net income/(loss)	$	113,118	$	67,697	$	(46,810)	$	134,005
Add/(deduct):
Interest expense		104		321		1,876		2,301
Income taxes		35,818		20,747		(10,401)		46,164
Depreciation		11,693		16,853		24		28,570
Amortization		53		5,236		-		5,289
EBITDA		160,786		110,854		(55,311)		216,329
Add/(deduct):
Intercompany interest expense/(income)		(12,717)		(9,088)		21,805		-
Interest income		(162)		(25)		(917)		(1,104)
Stock option expense		-		-		18,302		18,302
Long-term incentive compensation		-		-		3,753		3,753
Legal settlements		548		-		-		548
Acquisition expense		8		226		-		234
Adjusted EBITDA	$	148,463	$	101,967	$	(12,368)	$	238,062
2025
Net income/(loss)	$	88,249	$	71,858	$	(35,857)	$	124,250
Add/(deduct):
Interest expense		95		261		416		772
Income taxes		30,361		21,936		(9,758)		42,539
Depreciation		10,509		16,601		24		27,134
Amortization		52		5,091		-		5,143
EBITDA		129,266		115,747		(45,175)		199,838
Add/(deduct):
Intercompany interest expense/(income)		(10,750)		(7,900)		18,650		-
Interest income		(110)		(33)		(4,489)		(4,632)
Stock option expense		-		-		18,307		18,307
Long-term incentive compensation		-		-		3,510		3,510
Adjusted EBITDA	$	118,406	$	107,814	$	(9,197)	$	217,023

The "Footnotes to Financial Statements" are integral parts of this financial information.

CHEMED CORPORATION AND SUBSIDIARY COMPANIES
RECONCILIATION OF ADJUSTED NET INCOME
(in thousands, except per share data)(unaudited)


	Three Months Ended June 30,				Six Months Ended June 30,
	2026		2025		2026		2025
Net income as reported	$	67,703	$	52,493	$	134,005	$	124,250
Add/(deduct) pre-tax cost of:
Stock option expense		9,052		9,216		18,302		18,307
Amortization of reacquired franchise rights		2,352		2,352		4,704		4,704
Long-term incentive compensation		2,248		853		3,753		3,510
Legal settlements		548		-		548		-
Acquisition expense		68		-		234		-
Add/(deduct) tax impacts:
Tax impact of the above pre-tax adjustments (1)		(2,377)		(2,143)		(4,626)		(4,462)
Excess tax expenses/(benefits) on stock compensation		445		(50)		501		(513)
Adjusted net income	$	80,039	$	62,721	$	157,421	$	145,796

Diluted Earnings Per Share As Reported
Net income	$	5.13	$	3.57	$	9.97	$	8.43
Average number of shares outstanding		13,199		14,703		13,442		14,733

Adjusted Diluted Earnings Per Share
Adjusted net income	$	6.06	$	4.27	$	11.71	$	9.90
Average number of shares outstanding		13,199		14,703		13,442		14,733

(1) The tax impact of pre-tax adjustments was calculated using the effective tax rate of the operating unit for which each adjustment is associated.

The "Footnotes to Financial Statements" are integral parts of this financial information.


CHEMED CORPORATION AND SUBSIDIARY COMPANIES
OPERATING STATISTICS FOR VITAS SEGMENT
(unaudited)
	Three Months Ended June 30,						For the Six Months Ended June 30,
OPERATING STATISTICS	2026			2025			2026			2025
Net revenue ($000) (c)
Homecare	$	391,348		$	358,042		$	762,438		$	709,608
Inpatient		35,673			33,023			71,599			67,045
Continuous care		19,396			23,640			37,530			48,276
Other		6,206			5,747			11,783			11,092
Subtotal	$	452,623		$	420,452		$	883,350		$	836,021
Room and board, net		(3,938)			(3,892)			(7,196)			(7,417)
Contractual allowances		(4,844)			(3,984)			(9,921)			(6,304)
Medicare cap allowance		(500)			(16,375)			(2,875)			(18,700)
Net Revenue	$	443,341		$	396,201		$	863,358		$	803,600
Net revenue as a percent of total before Medicare cap allowance
Homecare		86.5	%		85.2	%		86.4	%		84.9	%
Inpatient		7.9			7.9			8.1			8.0
Continuous care		4.3			5.6			4.2			5.8
Other		1.3			1.3			1.3			1.3
Subtotal		100.0			100.0			100.0			100.0
Room and board, net		(0.9)			(0.9)			(0.9)			(0.9)
Contractual allowances		(1.1)			(0.9)			(1.1)			(0.8)
Medicare cap allowance		(0.1)			(3.9)			(0.3)			(2.2)
Net Revenue		97.9	%		94.3	%		97.7	%		96.1	%
Days of care
Homecare		1,792,360			1,662,455			3,483,979			3,295,024
Nursing home		303,053			307,158			597,871			614,266
Respite		12,307			11,440			23,182			21,435
Subtotal routine homecare and respite		2,107,720			1,981,053			4,105,032			3,930,725
Inpatient		29,703			28,213			60,177			57,917
Continuous care		18,094			21,647			35,382			44,267
Total		2,155,517			2,030,913			4,200,591			4,032,909

Number of days in relevant time period		91			91			181			181
Average daily census ("ADC") (days)
Homecare		19,697			18,269			19,249			18,205
Nursing home		3,330			3,375			3,303			3,394
Respite		135			126			128			118
Subtotal routine homecare and respite		23,162			21,770			22,680			21,717
Inpatient		326			310			333			320
Continuous care		199			238			195			244
Total		23,687			22,318			23,208			22,281

Total Admissions		19,125			17,545			38,519			35,684
Total Discharges		18,167			17,845			36,704			35,583
Average length of stay (days)		101.2			137.1			101.9			127.9
Median length of stay (days)		16.0			20.0			15.0			18.0

ADC by major diagnosis
Cerebro		44.2	%		44.4	%		44.4	%		44.6	%
Neurological		11.1			12.1			11.2			12.2
Cancer		9.5			9.7			9.5			9.6
Cardio		16.6			16.2			16.5			16.1
Respiratory		8.0			7.5			7.8			7.3
Other		10.6			10.1			10.6			10.2
Total		100.0	%		100.0	%		100.0	%		100.0	%
Admissions by major diagnosis
Cerebro		27.3	%		26.7	%		27.1	%		27.6	%
Neurological		7.1			7.2			7.0			6.8
Cancer		24.7			26.6			24.1			25.6
Cardio		15.2			14.9			15.5			15.0
Respiratory		11.8			10.7			12.1			11.1
Other		13.9			13.9			14.2			13.9
Total		100.0	%		100.0	%		100.0	%		100.0	%

Estimated uncollectible accounts as a percent of revenues		0.7	%		1.0	%		1.1	%		0.8	%

Accounts receivable --
Days of revenue outstanding-excluding unapplied Medicare payments		39.7			37.5			n.a.			n.a.
Days of revenue outstanding-including unapplied Medicare payments		26.9			26.9			n.a.			n.a.


CHEMED CORPORATION AND SUBSIDIARY COMPANIES
FOOTNOTES TO FINANCIAL STATEMENTS
FOR THE THREE AND SIX MONTHS ENDED JUNE 30, 2026 AND 2025
(unaudited)

(a)	Included in the results of operations for 2026 are the following significant credits/(charges) which may not be indicative of ongoing operations
	(in thousands):
		Three Months Ended June 30, 2026
		VITAS		Roto-Rooter		Corporate		Consolidated

	Stock option expense	$	-	$	-	$	(9,052)	$	(9,052)
	Amortization of reacquired franchise agreements		-		(2,352)		-		(2,352)
	Long-term incentive compensation		-		-		(2,248)		(2,248)
	Legal expense		(548)		-		-		(548)
	Acquisition expense		(8)		(60)		-		(68)
	Pretax impact on earnings		(556)		(2,412)		(11,300)		(14,268)
	Excess tax expenses on stock compensation		-		-		(445)		(445)
	Income tax benefit on the above		135		562		1,680		2,377
	After-tax impact on earnings	$	(421)	$	(1,850)	$	(10,065)	$	(12,336)

		Six Months Ended June 30, 2026
		VITAS		Roto-Rooter		Corporate		Consolidated

	Stock option expense	$	-	$	-	$	(18,302)	$	(18,302)
	Amortization of reacquired franchise agreements		-		(4,704)		-		(4,704)
	Long-term incentive compensation		-		-		(3,753)		(3,753)
	Legal settlements		(548)		-		-		(548)
	Acquisition expense		(8)		(226)		-		(234)
	Pretax impact on earnings		(556)		(4,930)		(22,055)		(27,541)
	Excess tax expenses on stock compensation		-		-		(501)		(501)
	Income tax benefit on the above		135		1,149		3,342		4,626
	After-tax impact on earnings	$	(421)	$	(3,781)	$	(19,214)	$	(23,416)

(b)	Included in the results of operations for 2025 are the following significant credits/(charges) which may not be indicative of ongoing operations
	(in thousands):
		Three Months Ended June 30, 2025
		VITAS		Roto-Rooter		Corporate		Consolidated

	Stock option expense	$	-	$	-	$	(9,216)	$	(9,216)
	Amortization of reacquired franchise agreements		-		(2,352)		-		(2,352)
	Long-term incentive compensation		-		-		(853)		(853)
	Pretax impact on earnings		-		(2,352)		(10,069)		(12,421)
	Excess tax benefits on stock compensation		-		-		50		50
	Income tax benefit on the above		-		546		1,597		2,143
	After-tax impact on earnings	$	-	$	(1,806)	$	(8,422)	$	(10,228)

		Six Months Ended June 30, 2025
		VITAS		Roto-Rooter		Corporate		Consolidated

	Stock option expense	$	-	$	-	$	(18,307)	$	(18,307)
	Amortization of reacquired franchise agreements		-		(4,704)		-		(4,704)
	Long-term incentive compensation		-		-		(3,510)		(3,510)
	Pretax impact on earnings		-		(4,704)		(21,817)		(26,521)
	Excess tax benefits on stock compensation		-		-		513		513
	Income tax benefit on the above		-		1,091		3,371		4,462
	After-tax impact on earnings	$	-	$	(3,613)	$	(17,933)	$	(21,546)


(c)	VITAS has 13 large (greater than 450 ADC), 24 medium (greater than 200 but less than 450 ADC) and 23 small (less than 200 ADC) hospice programs. Of Vitas' 33 Medicare provider numbers, for the current cap year, 22 provider numbers have a Medicare cap cushion of greater than 10%, seven provider numbers have a Medicare cap cushion between 0% and 10%, and four provider numbers have a Medicare cap liability.